Business Description
Sutro Biopharma Inc
NAICS : 325412
SIC : 2834
ISIN : US8693671021
Total Employee Number:
133Description
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 14.86 | |||||
Equity-to-Asset | -0.28 | |||||
Debt-to-Equity | -0.2 | |||||
Debt-to-EBITDA | -0.13 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -5.29 | |||||
Beneish M-Score | -0.94 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -3.3 | |||||
3-Year EBITDA Growth Rate | 7.7 | |||||
3-Year EPS without NRI Growth Rate | 13.9 | |||||
3-Year FCF Growth Rate | -191.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 29.69 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -33.13 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.83 | |||||
9-Day RSI | 45.91 | |||||
14-Day RSI | 48.02 | |||||
3-1 Month Momentum % | 0.89 | |||||
6-1 Month Momentum % | 113.33 | |||||
12-1 Month Momentum % | 219.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.12 | |||||
Quick Ratio | 3.12 | |||||
Cash Ratio | 2.86 | |||||
Days Sales Outstanding | 30.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.3 | |||||
Shareholder Yield % | -19.46 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -87.44 | |||||
Net Margin % | -154.21 | |||||
EBITDA Margin % | -105.52 | |||||
FCF Margin % | -152.74 | |||||
OCF Margin % | -152.2 | |||||
ROA % | -63.51 | |||||
ROIC % | -110.01 | |||||
3-Year ROIIC % | -53.37 | |||||
ROC (Joel Greenblatt) % | -429.38 | |||||
ROCE % | -71.3 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.67 | |||||
EV-to-EBIT | -2.71 | |||||
EV-to-EBITDA | -2.89 | |||||
EV-to-Revenue | 3.05 | |||||
EV-to-Forward-Revenue | 5.1 | |||||
EV-to-FCF | -1.99 | |||||
Price-to-GF-Value | 2.46 | |||||
Earnings Yield (Greenblatt) % | -36.9 | |||||
FCF Yield % | -30.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:STRO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sutro Biopharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 99.608 | ||
| EPS (TTM) ($) | -16.43 | ||
| Beta | 1.8794 | ||
| 3-Year Sharpe Ratio | 0.33 | ||
| 3-Year Sortino Ratio | 0.53 | ||
| Volatility % | 71.76 | ||
| 14-Day RSI | 48.02 | ||
| 14-Day ATR ($) | 2.834518 | ||
| 20-Day SMA ($) | 30.2025 | ||
| 12-1 Month Momentum % | 219.03 | ||
| 52-Week Range ($) | 7.15 - 43.85 | ||
| Shares Outstanding (Mil) | 16.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sutro Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sutro Biopharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 117 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 16:30 | In 27 days | ||
| General meeting for 2026 | 2026-06-05 08:00 | 28.68 (+5.87%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 09:20 | 27.18 (+10.85%) | ||
| TD Cowen 7th Annual Oncology Innovation Summit | 2026-05-27 12:30 | 27.38 (+8.26%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 39.60 (-2.68%) | ||
| Annual report for 2025 | 2026-03-23 | 20.68 (-0.39%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-23 | 20.68 (-0.39%) | ||
| Guidance call for 2026 | 2026-03-10 13:05 | 24.98 (-0.08%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-04 13:50 | 19.70 (-0.30%) |
Show
Entries
Sutro Biopharma Inc Frequently Asked Questions
What is Sutro Biopharma Inc(STRO)'s stock price today?
The current price of STRO is $29.71. The 52 week high of STRO is $43.85 and 52 week low is $7.15.
When is next earnings date of Sutro Biopharma Inc(STRO)?
The next earnings date of Sutro Biopharma Inc(STRO) is 2026-08-07 Est..
Does Sutro Biopharma Inc(STRO) pay dividends? If so, how much?
Sutro Biopharma Inc(STRO) does not pay dividend.
Guru Commentaries on NAS:STRO
No articles.
Press Release
Articles on Sutro Biopharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers